Abstract
In vivo toxicological analyses are crucial in demonstrating the efficacy of drugs in the treatment of diseases. Animal models are commonly used for in vivo toxicological and efficacy analysis of drugs. Nanoparticles-based drug formulations or nanomedicines are characterized with varying degrees of toxicity to target and/or nontarget cells in animal models. Hence, it is necessary to comprehensively evaluate nanomedicines to assess their toxicology and therapeutic indices in specific animal models as part of the drug discovery pipeline. Various animals have been used as live models for in vivo assessment of nanomedicines. This chapter discusses different types of in vivo animal models that are used to evaluate toxicity and efficacy of nanomedicines in diabetes treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Emerging Nanomedicines for Diabetes Mellitus Theranostics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
